Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus FLUTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus FLUTEX.
ALA-SCALP vs FLUTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Flutamide is a nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone (DHT) to androgen receptors in target tissues, thereby blocking the androgenic effects.
Topical application of a 5% solution to the scalp twice daily.
50 mg orally once daily
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life: 24–36 hours, permitting once-daily dosing in chronic therapy
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Renal: ~70% (50% unchanged, 20% as metabolites); Biliary/fecal: ~30%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid